IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announces it intends to offer up to $300.0 million in shares of common stock and, in lieu of common stock, to certain investors pre-funded warrants. On June 8, 2026, the company further announces the pricing of an underwritten public offering that includes both common stock and pre-funded warrants. According to the reports, IDEAYA sells 5,555,556 shares of common stock along with pre-funded warrants that are exercisable to purchase additional shares, with the offering structured so that the total gross proceeds target $300 million. One outlet reports the offering price as $27 per share. The pre-funded warrants are designed to provide investors with a way to purchase shares in the future while paying the exercise price up front. The offering details, including the number of shares and pre-funded warrants and the gross proceeds, are presented as part of a standard underwriting arrangement. The company’s announcements describe the offering and its pricing, without providing further commentary on use of proceeds in the materials provided.